Infusion-related side-effects in children undergoing autologous hematopoietic stem cell transplantation for acute leukemia
Bone marrow (BM) and peripheral blood (PB) autologous hematopoietic stem cell (SC) transplantation (AHSCT) have been widely adopted to reconstitute hematopoiesis after myeloablative chemotherapy to treat acute leukemia.
1,2 SC are usually added to a cryoprotective agent (DMSO) and frozen in liquid nitrogen until thawing and reinfusion. During the SC infusion, or in the following hours, many side-effects, which may be severe or lifethreatening, have been reported. [3] [4] [5] [6] They include hypo-or hypertension, anaphylactic reactions, heart and respiratory failure, possibly due to DMSO, fluid overload and RBC hemolysis induced by cryopreservation and thawing. Since few reports deal with this topic in children, we retrospectively investigated the incidence and severity of infusionrelated side-effects in 30 pediatric patients (19 M, median age 8 years, range: 2-18) who underwent AHSCT from 1994 to 1999 at the Pediatric Department of the Ospedale San Gerardo in Monza, for acute lymphoblastic leukemia (ALL) in second remission (n ϭ 20) or acute non-lymphoblastic leukemia (ANLL) in first remission (n ϭ 10). Six patients received unmanipulated BM, seven unmanipulated PB and 17 purged PB following CD34 ϩ cell negative (neg.sel.PB) or positive (pos.sel.PB) selection. Conditioning regimens included total body irradiation for 23 patients. The BM was collected as per standard procedure. 7 PBSCs were mobilized after high-dose chemotherapy followed by G-CSF 10 g/kg/day s.c. and collected by means of a continuous flow cell separator (Cobe Spectra; Cobe, Lakewood, CO, USA). Seven aphereses were not manipulated; in 17 cases PB manipulations consisted of negative selection for ALL (n ϭ 12) and positive selection for ANLL (n ϭ 5), performed by a SuperMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany) as described by Rambaldi et al. 8 SCs were frozen regardless of their nucleated cell concentration, without further centrifugation or dilution steps, 9 by slowly adding ACD-A (Baxter, Deerfield, IL, USA) and DMSO (Merck, Sharp & Dome, Darmstadt, Germany) in melting ice, up to a final concentration of 10% for both additives and then transferred into a freezing bag (NPBI, Emmer, The Netherlands). Freezing was performed using a programmable device.
At the time of infusion, hydrocortisone, clorpheniramine and hyper-hydration were administered to all patients; furosemide to prevent fluid overload and tropisetron to reduce nausea and vomiting were given to most patients. Vital signs (BP, HR, SO 2 ) and symptoms were monitored for 6 h after the infusion. Continuous EKG was recorded. Hypotension and hypertension were defined as a change of more than 20% compared to the basal value. Mild bradycardia repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996; 89: 3700-3707.
was defined as a decrease of more than 20%; severe bradycardia when the HR was Ͻ60. Thawing was performed rapidly at the bedside in a 42°C water bath and cells were infused through a CVC with a 170 m transfusion filter, at 10 ml/min. Viability was assessed by the 0.4% Trypan Blue dye exclusion method. 7 Blood chemistries were determined before and the day after infusion; urinalysis was performed twice daily. Myeloid engraftment was defined as the first of 3 consecutive days with an ANC Ͼ1 ϫ 10 3 /l and platelet engraftment as the first of 5 consecutive days with a platelet count Ͼ20 ϫ 10 3 /l without transfusion support.
Characteristics of the grafts are reported in Table 1 . Patients given unmanipulated PB received the highest number of nucleated cells (NC), DMSO/kg, and volume (median: 240 ml, range: 100-555); BM specimens showed the highest hematocrits, but the median number of RBC/kg infused was similar for BM and unmanipulated PB recipients. The highest median CD34 ϩ cells/kg was contained in the pos.sel.PB products; the NC concentration in pre-frozen products ranged from 1.7 ϫ 10 6 /ml in pos.sel.PB samples to 128 ϫ 10 6 /ml in unmanipulated PB (data not shown). Post-thawing NC viability was higher in PB samples compared to BM, the highest values being observed in pos.sel.PB specimens.
All 32 procedures (two patients received infusions on 2 consecutive days) were well tolerated. Infusion-related side-effects were observed in 15 of 32 infusions (47%), but none required specific therapy: nine patients had mild heart rate decreases (three BM recipients, two PB, four neg.sel.PB), one abdominal pain (neg.sel.PB), two headache (one BM, one pos.sel.PB) and three hemoglobinuria (all BM recipients); no severe bradycardia or major problems were observed. No relevant variations were observed in blood chemistries the day after infusion (data not shown). All patients showed a prompt hematopoietic reconstitution; patients receiving PB, either manipulated or not, engrafted earlier than BM recipients.
It is well known that DMSO can induce histamine release, 3 which in turn may be responsible for flushing, pulmonary distress, abdominal cramps, and cause various degrees of cardiovascular changes, such as hypotension, hypertension and bradycardia. 3, 4 Even severe arrhythmias and atrio-ventricular conduction blocks have been described, 4, 6, 10, 11 which have also been attributed either to the vagotonic effect of DMSO, or to the electrolyte abnormalities induced by red cell hemolysis, or to fluid overload. These side-effects have been observed mostly with the infusion of large amounts of DMSO, mainly in BM recipients. Post-thawing RBC hemolysis might cause several complications, such as damage to proximal renal tubules, fever and damage to endothelial cells with subsequent thromboplastin production and activation of coagulation factors, with subsequent complement activation and further anaphylotoxin release. 12 Cryopreserved SCs infusionrelated side-effects varies widely in hitherto reported series, depending on several factors: product type (BM, PB, manipulation), amount of volume/kg infused, DMSO concentration, product hematocrit, and finally, premedication schedule. Stroncek et al 4 reported an overall incidence of side-effects of 76% in a series of 135 patients with a mean age of 19 years. Most complained of nausea (48%) and vomiting (24%), and three patients showed symptoms attributable to fluid overload. In this report, however, no information is given about the premedication schedule. Nausea and vomiting were the most frequent side-effects even in the adult patients reported by Davis et al. 3 Moreover, the authors reported an asymptomatic HR decrease in 98% of 4-hydroperoxy-cyclophosphamide-treated graft recipients and in all recipients of untreated grafts. The mean age of these patients was 30 years and they were all administered hydration, hydrocortisone and diphenhydramine prior to infusion. More recently, Alessandrino et al 6 observed noncardiovascular complications in 19% and 8% of BM and PB recipients, respectively; severe bradycardia (HR 35/min) was observed in two patients, another one showed heart block which required resuscitation; asymptomatic hypotension was observed in 21% and hypertension in 36% of PB recipients. All BM recipients, who were given products with a median hematocrit of 26% (range: 24-29), had hemoglobinuria; both BM and PB recipients were given methylprednisolone before infusion. Nausea (68%), vomiting (46%) and headache (70%) were the most frequent side-effects in 52 pediatric patients, all receiving i.v. steroids and hydroxyzine before infusion, reported by Okamoto et al. 12 In this latter patient series, however, 15% of the patients showed a 'transient shock' condition.
In our pediatric series, no severe infusion-related sideeffects were reported and no children showed life-threatening conditions; the observed overall incidence of 47% included asymptomatic HR decrease (28%), and transient hemoglobinuria (9%). Most side-effects were observed in Bone Marrow Transplantation BM recipients, while patients receiving PB products, either manipulated or not, showed minimal complaints. We believe that these very limited side-effects might be attributed to the product characteristics and the premedication schedule adopted. With regard to the former, the products (both BM and PB samples) had a very low hematocrit (maximum value 9%), which greatly reduced hemolysisrelated side-effects. Our single step cryopreservation technique, which is aimed at limiting the total amount of DMSO, proved to be effective in avoiding most of the DMSO-related toxicity and did not compromise either postthawing NC viability or engraftment, as previously reported.
1,2 The premedication schedule routinely adopted before infusion proved to be effective in avoiding most of the usually observed infusion-related side-effects, even though it is known that antihistaminic drugs may induce bradycardia. 6 The mild sedation which is usually triggered by the i.v. administration could also be helpful in enhancing the children's compliance to the infusion procedure, which can be a very stressful event.
A reduction of infusion-related side-effects could also be achieved by washing thawed products before infusion by means of automated devices to remove DMSO, cell debris and free hemoglobin. 13 This method proved to be effective, with NC and CD34 ϩ cell recovery Ͼ85%, but it is costly and time-consuming. Furthermore, most RBC hemolysisinduced side-effects, could be almost completely avoided with a careful processing of BM before freezing in order to reduce product volumes and RBC contamination, by either using a cell separator 14 or adding an erythrocyte sedimentating agent such as 6% HES.
In conclusion, we believe that the best way to avoid severe infusion-related side-effects is a combination of the above-reported techniques and therapeutic schedules. In fact, the very low incidence and severity of infusion-related side-effects in our patient series suggests that the lower the product volume and DMSO/kg infused (particularly if RBC contamination is minimal) the higher is the probability of an uneventful SC infusion. 
